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ABSTRACT 
 
Due to the essential roles of glutamate, detection and response to a large range of extracellular 
concentrations of this excitatory amino acid are necessary for the fine-tuning of brain functions. Metabotropic 
glutamate receptors (mGluRs) are implicated in shaping the activity of many synapses in the central nervous 
system. Among the eight mGluR subtypes, there is increasing interest in studying the mGlu3 receptor which 
has recently been linked to various diseases, including psychiatric disorders. This receptor displays striking 
functional properties, with a high and, often, full basal activity, making its study elusive in heterologous 
systems. Here, we demonstrate that Cl- ions exert strong positive allosteric modulation of glutamate on the 
mGlu3 receptor. We have also identified the molecular and structural determinants lying behind this allostery: 
a unique interactive “chloride-lock” network. Indeed, Cl- ions dramatically stabilize the glutamate-induced 
active state of the extracellular domain of the mGlu3 receptor. Thus, the mGlu3 receptors’ large basal activity 
does not correspond to a constitutive activity in absence of agonist. Instead, it results mostly from a Cl—
mediated amplified response to low ambient glutamate concentrations, such as those measured in cell media. 
This strong interaction between glutamate and Cl- ions allows the mGlu3 receptor to sense and efficiently react 
to sub-micromolar concentrations of glutamate, making it the most sensitive member of mGluR family.  
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HIGHLIGHTS 
• Chloride ions are strong positive allosteric modulators of mGlu3 receptor 
• A unique “chloride-lock” network dramatically stabilize the active state of the receptor 
• This allows the mGlu3 receptor to sense and react to sub-micromolar concentrations of glutamate 
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INTRODUCTION 
The amino acid L-glutamate is an essential element of life, and has been very early used as a messenger. 
During evolution, L-glutamate became one of the major neurotransmitters, being the mediator of the neuro-
muscular junction in arthropods and being responsible for transmitting signals at most fast excitatory synapses 
in the brain (Fonnum, 1984). Such an essential role of glutamate, associated with all the other functions of this 
amino acid, imposes a tight regulation of its extracellular concentrations. Indeed, an inaccurate control of 
extracellular glutamate levels can lead to epilepsy and brain damage through excitotoxicity (Meldrum, 2000). 
Essential mechanisms have then been selected during evolution to monitor extracellular glutamate 
concentrations, including active uptake mechanisms and a control of glutamate entry at the level of the blood 
brain barrier. Defects in these mechanisms have been proposed to be responsible for a number of brain diseases, 
including neurodegenerative disorders as well as psychiatric diseases or addiction (Kalivas, 2009; Lewerenz 
and Maher, 2015; Miladinovic et al., 2015). 
Glutamate activates cationic glutamate-gated channels (i.e. ionotropic glutamate receptors) that mediate 
the fast excitatory actions of glutamate. It also activate G protein-coupled receptors, named metabotropic 
glutamate receptors (mGluRs) (Pin and Bettler, 2016). The eight subtypes of mGluRs are key modulators of 
transmission at most synapses in the brain. Some mGluRs are located post-synaptically (the group-I mGlu1 
and mGlu5), allowing a tight control of the post-synaptic response, while others (group-II, mGlu2 & 3, and 
group-III, mGlu4, 7 & 8) are mainly found in pre-synaptic terminals where they inhibit the release of various 
neurotransmitters. Aside from the group-III mGlu6, which is responsible of the ON-bipolar neuronal 
transmission in the retina (Vardi et al., 2000), mGluRs can be considered as glutamate sensors allowing cells 
to adapt their response as a function of the extracellular glutamate concentration. Indeed, mGluRs are not only 
found at glutamatergic synapses, but also at other types of synapses, including dopaminergic (DA) and 
GABAergic synapses, as well as in other regulatory cells such as astrocytes and microglial cells (Nicoletti et 
al., 2011). 
All mGluRs share a common structural architecture (Pin and Bettler, 2016). They are obligate dimers, each 
protomer being composed of a large bi-lobed extracellular domain (ECD) containing a Venus Flytrap (VFT) 
and a cysteine-rich domain (CRD) that connects to the seven helices transmembrane spanning domain (TMD). 
The VFT domain binds orthosteric ligands and also endogenous allosteric modulators, notably extracellular 
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ions, such as calcium and chloride, that potentiate receptor activity (DiRaddo et al., 2014; Jiang et al., 2014; 
Kuang and Hampson, 2006; Kubo et al., 1998; Tora et al., 2015; Vafabakhsh et al., 2015).  
The group-II mGlu3 receptor is found at the post-synapse and in pre-synaptic elements in neurons and in 
astrocytes, facing the micro-vessels, making this receptor a likely key component of the detection of the 
extracellular glutamate concentration (Mudo et al., 2007; Ohishi et al., 1993; Tamaru et al., 2001). Genetic 
studies revealed a possible involvement of this receptor in various diseases, including schizophrenia and other 
psychiatric disorders (Consortium, 2014; De Filippis et al., 2015; Egan et al., 2004; Harrison et al., 2008; 
O'Brien et al., 2014), as well as cancer development at the periphery (Kunz, 2014; Yi et al., 2017). When 
compared to other mGlu receptor subtypes, mGlu3 receptor often displays a strong basal activity in transfected 
cells, therefore limiting their full functional and pharmacological characterization. 
The present study aimed to elucidate the structural and molecular basis of the high basal activity of the 
mGlu3 receptor detected in heterologous system, a surprising property given its high structural similarity with 
the mGlu2 receptor that does not display the same behavior. We demonstrate the existence of a unique allosteric 
interaction between glutamate and Cl- ions in the mGlu3 receptor. This strengthened interaction network 
increases the stability of the glutamate-induced active state of the extracellular domain of the receptor, making 
the mGlu3 receptor highly responsive to low ambient glutamate concentrations Finally, we propose that this 
mechanism allows an accurate detection of sub-micromolar extracellular glutamate concentrations. 
  
6 
 
MATERIAL AND METHODS 
 
Cell culture and transfection 
 
HEK293 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies, Cergy 
Pontoise, France), supplemented with 10% of Fetal Bovine Serum (FBS) and were transiently transfected with 
rat mGluRs receptors by electroporation or reverse lipofectamine 2000 protocol as previously described 
(Doumazane et al., 2013). Receptors were also co-transfected with the glutamate transporter EAAC1 to 
minimize influence of extracellular glutamate and if needed, chimeric Gi/Gq G-protein (GqTOP) to allow the 
coupling to the phospholipase C pathway for second messenger experiments. Cells were seeded in a poly-
ornithine coated 96-well plate at the density of 150 000 cells/well. 24h (48h for chimeras) after transfection, 
medium was changed by GlutamaxTM (Life Technologies, Cergy Pontoise, France) to reduce extracellular 
glutamate concentration 2 hours before experiments. 
 
Directed mutagenesis and chimeras constructs 
 
mGlu3 mutants receptors were obtained using the Quick-Change strategy (Stratagene, La Jolla, CA, USA). 
All mutations were made in the HA and HA SNAP encoding plasmids and were verified by sequencing. Total 
and cell surface expression was quantified by ELISA using anti-HA primary antibody coupled to peroxidase 
(3F10, Roche, Basel, Switzerland) as previously described (Goudet et al., 2004). For chimeras receptors, a 
restriction site was introduced after the Venus Flytrap (VFT) encoding sequence in HA SNAP mGlu2 and 
mGlu3 plasmids using the Quick-Change strategy. Then, digested VFT sequences were sub-cloned into mGlu2 
or mGlu3 plasmids according chimera design and final constructs were also verified by sequencing. Chimeras 
expression levels were quantified by fluorescence at 620 nm on Lumi4-Tb labeled receptors as described 
elsewhere (Doumazane et al., 2013). 
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Chloride buffers composition 
 
All chemical products were purchased from Sigma-Aldrich (L’Isle d’Abeau, France). Reference high Cl- 
buffer used for calcium mobilization, TR-FRET mGlu sensor and smFRET assays contained 154.6 mM of Cl- 
ions and included NaCl 150 mM, KCl 2.6 mM, MgSO4 1.18 mM, D-glucose 10 mM, HEPES 10 mM, CaCl2 
1 mM and 0.5% (w/v) BSA. To reach 200 mM Cl- concentration, NaCl was increased. For buffers with lower 
Cl- concentration, NaCl and KCl were progressively replaced by gluconate equivalents (NaC6H11O7 and 
KC6H11O7 respectively). pH was adjusted at 7.4. It was previously shown that gluconate does not impair cell 
signaling (Tora et al., 2015). 
 
Second messengers assays 
 
Inositol monophosphate production was determined using the IP-One HTRF (Homogenous Time Resolved 
Fluorescence) kit (Cisbio Bioassays, Codolet, France) according to the manufacturer’s recommendations 
(Trinquet et al., 2006). For the calcium mobilization assay, HA tagged mGluRs expressing cells were seeded 
in black-walled, clear bottom 96-well plates. High (154.6 mM) and low (2 mM) Cl- buffers supplemented with 
4 mM probenecid were used. 24h after transfection, cells were loaded with 1 μM of calcium sensitive 
fluorescent dye Fluo 4-AM (Life Technologies, Cergy Pontoise, France) diluted in fresh high Cl- buffer, for 
1h at 37°C. After washing, cells were maintained in 2 or 154.6 mM Cl- buffers prior glutamate addition. 
Intracellular calcium release was determined using Flexstation®3 (Molecular Devices, Sunnyvale, CA, USA). 
Fluorescence was detected for 60 seconds at 485 nm excitation and 525 nm emission. In order to assess 
gluconate side effects on cell signaling, Ca2+ mobilization was also measured after stimulation of an AVP 
sensitive endogenous receptor on non-transfected cells, which was used as an internal control in each 
experiment, as previously described (Tora et al., 2015) . 
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TR-FRET mGlu sensor assay 
 
SNAP tagged mGluRs were used for this assay. Cells were seeded in black-walled, black bottom 96-well 
plates. 24 hours (48 hours for chimeras) after transfection, receptors were covalently labeled with 100 nM of 
SNAP-Lumi4-Tb (donor) and 60 nM of SNAP-Green (acceptor) diluted in 154.6 mM high Cl- buffer. Donor 
and acceptor concentrations were chosen in order to label surface receptors equivalently, with both 1 donor 
and 1 acceptor molecule. After 1 hour at 37°C, cells were washed in appropriate Cl- buffers and drugs were 
added. TR-FRET measurements were collected at 520 nm using PHERAstar F5 microplate reader as 
previously described (Doumazane et al., 2013). 
 
Data analysis 
 
IP-One, Ca2+ mobilization and TR-FRET data were analyzed with Prism 6 software (GraphPadSoftware, 
San Diego, CA, USA). Concentration-responses curve parameters were derived using a four-parameter non-
linear regression equation. For clarity, potency was expressed as absolute (positive) logarithms (pEC50) and 
nH (Hill slope) describes the steepness of the curve. In Cl- experiments, data from Ca2+ mobilization were 
normalized by the WT receptor maximum response obtained in 2 mM Cl- buffer and Emax represent the 
maximum response obtained at saturating agonist concentration. In TR-FRET mGlu sensor assay, base and 
maximum of the curve were normalized by high and low FRET ratio of the WT receptor in 2 mM Cl- buffer 
to define respectively 100% and 0% of the signal. For chimeras experiments, data were normalized by mGlu2 
receptor maximum window (top and bottom of mGlu2 receptor curve). Data shown in the figures represent the 
mean ± S.E.M. of at least three experiments performed at least in duplicates. Statistical differences were 
determined by One-way ANOVA with Dunnett’s and Sidak’s post-test. 
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smFRET experiments 
 
For smFRET experiments, human SNAP tagged mGluRs extracellular domains (ECD) fused to a GPI 
anchor in the C-terminus (HA SNAP mGlu3 Del570 GPI) were transiently co-transfected with glutamate 
transporter EAAC1 in HEK293 TSA cells by reverse Lipofectamine 200 protocol (Life Technologies, Cergy 
Pontoise, France), in 6-well plates. After 24 hours expression, receptors were covalently labeled with 100 nM 
Benzyl-Guanine-Cy3B (donor) and 1 µM Benzyl-Guanine-d2 (acceptor) (Cisbio Bioassays, Codolet, France) 
diluted in fresh 154.6 mM high Cl- buffer for 1 hour at 37°C. Then several washings with different Cl- buffers 
were performed prior to ECD cleavage using 0.25 U.ml-1 Bacillus cereus Phosphatidylinositol-specific 
Phospholipase C (Life Technologies, Cergy Pontoise, France), at 37°C for 30 minutes. ECD were purified 
using ZebaTM spin desalting columns (Life Technologies, Cergy Pontoise, France) and stored at -20°C 
supplemented with 50% glycerol and 0.1 mg.ml-1 BSA. For smFRET measurements, samples were diluted to 
picomolar concentration and loaded into 384-well plates (Greiner Bio One). Data acquisition was performed 
on our home-built confocal MFD-PIE (Multiparameter Fluorescence Detection – Pulsed Interleaved 
Excitation) microscope (Olofsson and Margeat, 2013) as previously described  (Olofsson et al., 2014). Data 
analysis was performed using the Software Package for Multiparameter Fluorescence Spectroscopy, Full 
Correlation and Multiparameter Fluorescence Imaging developed in C.A.M. Seidel lab (http://www.mpc.uni-
duesseldorf.de/seidel/)(Widengren et al., 2006). Pulsed interleaved excitation allowed us to construct the 2D-
histogram of the proximity ratio EPR (i.e. FRET efficiency) and stoichiometry ratio S, where single-labeled 
species and/or free fluorophores can be excluded, and only double-labeled species are selected for further 
analysis. Apparent EPR histograms were analyzed using Origin® 8. At least three measurements were performed 
for each sample and data shown in the figures represent the mean ± S.E.M. Statistical differences were 
determined by One-way ANOVA with Sidak’s post-test. 
Binding assay 
 
For ligand binding assay, membranes from mGluRs transfected HEK293 cells were prepared. After 48 
hours expression, cells were washed with cold PBS, scratched and collected by centrifugation at 4°C. Then 
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membranes were prepared by successive homogenization (on ice) and centrifugation (1000 rpm at 4°C) steps. 
After a final centrifugation at 19 500 rpm for 2 hours at 4°C, membranes were resuspended in sensor buffer 
(high Cl-), quantified by BCA method and stored at -80°C. For binding assay, 15-20 μg of mGlu2 or mGlu3 
membranes were incubated respectively with 5 or 3 nM [3H]-LY341495 (corresponding to Kd of this 
radioligand) and various concentrations of cold glutamate for 1h at room temperature. Membranes were then 
collected on filters and washed 3 times with a 0.9% NaCl solution. Filters were placed in tubes containing a 
liquid scintillation mixture solution, and radioactivity was measured with a Packard beta counter (Perkin 
Elmer). Unspecific binding was determined in presence of 100 μM LY379268. Data were analyzed with Prism 
6 software (GraphPadSoftware, San Diego, CA, USA) to determine Ki values. 
 
Glutamate quantification 
 
Medium from plated cells transiently expressing mGluRs with or without EAAC1 transporter was sampled 
for glutamate analysis at different experiment times: after 24 hours expression, cells were washed one time 
and let 15 min in sensor assay buffer (high Cl-); then 2 hours or 5 hours after medium change by GlutamaxTM. 
GlutamaxTM medium, IP-One and high Cl- Ca+/sensor assay buffers were also tested. Samples were filtered on 
0.2-0.8 μm filters prior to analysis. 
Glutamate quantification was performed by a reversed phase narrow bore liquid chromatography assay 
with fluorescence detection after precolumn derivatization with o-phtalaldehyde and β-mercaptoethanol, as 
previously described (Van Hemelrijck et al., 2005). The compounds were eluted by gradient elution with a 
mobile phase that was delivered at a rate of 0.17 mL/min. The gradient elution was performed using mobile 
phase A (0.025 M sodium phosphate solution pH 9 and 1% tetrahydrofuran) and mobile phase B 
(methanol:water 90:10). The temperature of the autosampler tray was set at 4°C and the injection volume was 
10 µL on a C18 narrow bore column (5 µm particle size, 250 x 2 mm, Capcell Pak MG®, Shiseido). Detection 
was performed with a RF 10A XL fluorescence detector (Shimadzu) at excitation and emission wavelengths 
of 340 and 450 nm, respectively. Data acquisition was carried out with the integration computer program 
Clarity (DataApex, Antec, Zoeterwoude, the Netherlands). All analyses were performed at least in duplicate. 
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Structural and sequence analysis 
 
Crystal structures of mGlu2 (PDB 4XAQ) and mGlu3 receptors (PDB 5CNK, 2E4U) were used to compare 
their VFT domains using the Discovery Studio 4.0 software (BIOVIA – A Dassault Systèmes brand – 5005 
Wateridge Vista Drive, San Diego, CA 92121 USA). For multiple sequence alignment, we used Discovery 
Studio’s tool Align123 based on the ClustalW program (Thompson et al., 1994). Sequences were obtained 
from Uniprot website (http://www.uniprot.org/), using the gene names for the queries, and only the sequence 
of the extra-cellular domain (ECD) was kept for the alignment. Output alignment was then further optimized. 
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RESULTS 
 
The glutamate binding domain is involved in the high basal activity of the mGlu3 receptor 
 
First, we compared the glutamate-induced production of second messengers by the different mGluRs. 
Receptors were transiently transfected in HEK293 cells and their glutamate-induced signaling responses were 
evaluated by measuring inositol monophosphate (IP1) production (Fig.1A). To allow the Gi–coupled group-II 
and –III mGluRs to activate the phosphoinositides pathway, receptors were co-transfected with a Gi/Gq 
chimeric G-protein. We found that the basal IP1 production was very high in mGlu3-expressing cells, in 
contrast to cells expressing other mGluR subtypes (p<0.001), such that glutamate addition did not induce a 
significant increase of IP1 production. 
To understand the structural origin of this phenomenon, we compared the activity of the mGlu3 receptor 
to its closest relative mGlu2 and built mGlu2/3 receptor chimeras by inverting their VFT domains. We then 
measured their activity using both functional (IP1 production) and conformational mGluR sensors (Fig.1B-C, 
supplemental figure 1 and supplemental table 1). These latter are based on VFT conformational changes 
occurring during receptor activation. SNAP-tags are inserted at the N-termini of each mGluR subunit and are 
covalently labeled with fluorescent dyes. Variation in distance between the fluorophores can be measured 
using Lanthanide Resonance Energy Transfer (LRET), using a Time-Resolved Förster Energy Transfer 
approach (TR-FRET) (Doumazane et al., 2013; Scholler et al., 2017). Agonist binding induces closure of 
mGluRs VFT domains, leading to a reorientation of the protomers increasing the distance between the N-
termini and so, resulting to a large decrease in the TR-FRET signals (Fig.1D).  
In contrast to what was observed with the mGlu2 receptor, glutamate concentration-response curves from 
mGlu3 receptor-expressing cells were nearly flat in both the IP1 and TR-FRET assays (Fig.1B-C). In vehicle 
conditions, the low FRET ratio measured for mGlu3 receptors suggested most receptors were mainly in an 
active conformation, despite the lack of glutamate addition (Fig.1C, supplemental table 1). This result, 
combined with high IP1 levels in the same condition, highlights the high basal activity of mGlu3 receptors. 
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When mGlu2 VFT was fused to mGlu3 TMD (VFT2/TMD3 chimera), this basal activity was abolished and the 
receptor could be activated by glutamate similarly to the mGlu2 receptor. In contrast, the fusion of mGlu3 VFT 
with mGlu2 TMD (VFT3/TMD2 chimera) showed an enhanced basal activity and a nearly flat glutamate 
concentration-response curve, similar to the mGlu3 receptor (Fig.1B-C, supplemental table 1). Taken 
together, these findings revealed that mGlu3 VFT domain plays a key role in the high basal activity of the 
receptor.  
 
Glutamate is required for the mGlu3 receptor high basal activity 
 
To explore the potential involvement of glutamate in the high basal activity of mGlu3 receptors, we first 
measured conformational changes in presence or absence of the competitive antagonist LY341495 (Fig.2A). 
Interestingly, in presence of LY341495, the FRET ratio is significantly increased (p<0.001) in comparison to 
the ratio measured in the vehicle condition. These results suggest either that LY341495 is an inverse agonist, 
or that possibly it competes with ambient glutamate present in the assay medium, preventing its action on the 
receptor. 
We then designed a mutant mGlu3 receptor less sensitive to glutamate. To that aim, we mutated the 
threonine in position 174, a key residue involved in the binding of the amino acid moiety of glutamate (Acher 
and Bertrand, 2005), into an alanine. We then measured the conformational changes of mGlu3 T174A in 
comparison to the WT mGlu3 receptor. As expected, the mGlu3 T174A construct was not activated by 
glutamate, except at high concentrations (1 mM) where a small decrease in the FRET ratio was measured. 
Interestingly, contrary to WT receptor, the mGlu3 T174A mutant did not display any basal activity (Fig. 2B). 
Decreasing receptor affinity for glutamate strongly reduces its basal activity, further supporting a key role of 
ambient glutamate provided by the cells in such an assay.   
We quantified the ambient glutamate concentrations in cell media and buffers used for our experiments 
(table 1). The glutamate concentration in cell medium is strongly affected by incubation time after transfection 
and co-expression of high-affinity glutamate transporter EAAC1. In optimized experimental conditions (i.e. 
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EAAC1 co-expression and 2 hours incubation in a glutamate-free cell medium before experiments, see 
Material and Methods section for details), a residual glutamate concentration of 0.59 ± 0.03 μM was measured.  
To correlate this result to glutamate affinity, we performed binding experiments on mGlu2 and mGlu3 
receptors expressing membranes (supplemental Fig.2). Radiolabeled LY341495 displacement curves 
indicated that the mGlu3 receptor has a higher affinity for glutamate (sub-micromolar range, 0.90 ± 0.31 μM) 
compared to its homolog mGlu2 receptor (ten micromolar range, 10.95 ± 6.92 μM). Of note, the glutamate Ki 
value of the mGlu3 receptor calculated from binding experiments correlated to the extrapolated potency derived 
from conformational sensor experiments in Fig.3 (0.88 vs. 0.90 μM) (supplemental table 2). According to 
the glutamate concentration in the assay, we can deduce that about 40% of the receptors are occupied in these 
conditions.   
Altogether, these results are highlighting that high basal activity likely of the mGlu3 receptor results mainly 
from receptor activation by ambient glutamate. 
 
Extracellular chloride modulates both basal and agonist-induced mGlu3 receptor activity 
 
We have previously reported the positive allosteric modulation of mGluRs’ activity by Cl- (Tora et al., 
2015), with the mGlu2 receptor being the less sensitive to extracellular Cl- as compared to other mGluRs. In 
that study, the effect of Cl- on mGlu3 receptor was not considered. However, another study proposed that Cl- 
ions could directly activate mGlu3 receptor (DiRaddo et al., 2015). In the light of these findings, we thus 
examined the effect of extracellular Cl- on mGlu3 receptor basal and agonist-induced activity.   
First, the receptor activity was measured both by functional (intracellular Ca2+ mobilization) and 
conformational assays (TR-FRET mGlu sensor assay) in two different buffers containing either a physiological 
(154.6 mM, referred to “high Cl-”) or a low Cl- concentration (2 mM, referred to “low Cl-”), where Cl- ions 
were replaced by gluconate equivalents to maintain osmolarity. In the functional assay, the glutamate 
concentration-response curve of mGlu3 was nearly flat in high Cl- buffer, whereas a robust dose-dependent 
activation of mGlu3 receptors by glutamate can be observed in the low Cl- buffer (Supplemental Fig.3 
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supplemental table 2). In the conformational assay, a concentration-dependent change of FRET signal was 
observed in both high and low Cl- buffers (Fig.3A). However, in the basal condition, the TR-FRET ratio in the 
high Cl- buffer is approximately half of the ratio observed in the low Cl- buffer (Fig.3A, supplemental table 
2).  
Positive cooperativity between Cl- and glutamate is further highlighted in figure 3B. Increasing 
extracellular Cl- concentration potentiated both receptor basal activity and glutamate potency, in a 
concentration-dependent manner. To quantify the Cl- effect, we plotted FRET ratios from Fig.3B to define a 
Cl- concentration-response curve either in vehicle condition or in presence of 30 μM of glutamate (the latter 
corresponds to a concentration engendering 80 % of the maximal response (i.e. EC80), in high Cl-) (Fig.3C). 
At EC80, Cl- potency was estimated to 30.98 mM, indicating a strong positive modulation on mGlu3 receptors. 
The Hill slope value was 1.11 ± 0.24, suggesting Cl- effect may occur predominantly at one binding site. 
Interestingly, in absence of glutamate addition, Cl- concentration-response curve was not well defined, but Cl- 
potency could be extrapolated to 470.10 mM, a concentration far above the physiological range which is 
considered to be around 120 mM (Jiang et al., 1992). Taken together, these findings indicate mGlu3 receptor 
is highly modulated by Cl-, in contrast to its homolog mGlu2 (Fig.3D).  
We then measured conformational changes in presence or absence of the competitive antagonist 
LY341495 in low and high Cl- buffers (Fig.3E). Interestingly, contrary to what is observed in high Cl- buffer 
(Fig.2A), LY341495 did not change the FRET ratio in low Cl- buffer as compared to the vehicle condition. 
These results suggest that reducing the mGlu3 receptor affinity for glutamate by depleting extracellular Cl- 
dramatically decreases its basal activity, in line with the results obtained with the insensitive mutant mGlu3 
T174A receptor.  
Taken together, these results highlight the link between extracellular Cl- concentration, glutamate and the 
mGlu3 receptor’s basal activity. They suggest that the high basal activity of the mGlu3 receptor may result from 
Cl- potentiation of the activity induced by residual glutamate.  
 
Chloride ions favor agonist-induced conformational change of the mGlu3 receptor 
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To better understand the consequence of Cl- modulation on the receptor, we further analyzed the glutamate-
induced conformational changes at the single molecule (smFRET) level in comparison to the ensemble level 
(TR-FRET) (Fig.4).  
Compared to ensemble FRET, smFRET allows the measurement of sub-millisecond conformational 
dynamics, thus providing a more accurate analysis of receptor activation mechanisms (Olofsson et al., 2014). 
We used isolated SNAP-tagged mGlu3 extracellular domains (ECD) for smFRET experiments, as previously 
described for mGlu2 receptors (Olofsson et al., 2014). This glycosylphosphatidyl inositol (GPI)-fused construct 
is cleaved by phospholipase C (PLC) in order to produce soluble ECDs, labeled with smFRET compatible 
fluorophores (Fig.4B, upper panel). Like full-length receptors, soluble ECDs oscillate between an active and 
an inactive state. This conformational equilibrium is affected by ligand binding, therefore shifting the apparent 
FRET efficiency (EPR) of the main population in smFRET experiment on diffusing molecules (Fig.4B, lower 
panel). Moreover, the use of highly diluted solutions of purified ECDs allows working with solutions 
containing very low ambient glutamate concentrations. 
We tested the effect of Cl- concentrations (2, 75 and 154.6 mM) on basal conditions (vehicle) or following 
glutamate addition on WT mGlu3 receptor or on mGlu3 T174A mutant, which is less sensitive to glutamate. 
Both TR-FRET and smFRET data confirmed the effect of Cl- on the equilibrium shift of the WT receptor dimer 
toward the active state, as seen both on basal activity (vehicle condition) and glutamate-induced FRET 
changes. In contrast, we observed that mGlu3 T174A is not activated by glutamate, as expected, nor by Cl- 
(Fig.4A and C, supplemental Fig.4). Therefore, the Cl- ion appears as a strong positive allosteric modulator 
of the mGlu3 receptor but did not display agonism by itself. Taking together, these results further confirm that 
the basal activity of mGlu3 is due to the receptor’s high affinity for glutamate and Cl- potentiation of glutamate 
binding. 
 
A unique “chloride lock” stabilizes the active state of the mGlu3 receptor 
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To delineate a molecular basis of the mGlu3 receptor’s Cl--related basal activity, we examined the crystal 
structures of mGlu3 and mGlu2 VFTs (PDB 5CNK and 4XAQ, respectively), recently solved in their dimer 
active closed conformation (Acc) binding the potent agonist LY354740 and glutamate (Glu) respectively 
(Monn et al., 2015a; Monn et al., 2015b) (Fig.5).  
A first difference resides in the number of Cl- binding sites in mGlu2 and mGlu3 VFTs. Several halide sites 
can be observed in mGlu3 VFT (Figure 5A-B). Among them, two sites correspond to functional Cl- binding 
sites that have been described in the VFT of most mGluRs, contrary to the mGlu2 receptor, which possesses 
only one of these functional sites (Tora et al., 2015). The first Cl- site (Site 1) is located within VFT lobe 1, in 
a binding pocket adjacent to the glutamate binding site, which was previously predicted (Acher et al., 2011) 
and demonstrated to be a Cl- binding site conserved in all mGluRs (Supplemental Fig.6A) (DiRaddo et al., 
2015; Tora et al., 2015). The second site (Site 2) is created by the interface of both VFT lobes, when the 
receptor is in a closed active conformation and shows more divergence within the mGluR family. This binding 
site is absent in mGlu2 where the S152 that is critical for Cl- binding in site 2 is replaced by an aspartate residue 
(Tora et al., 2015). 
Another major difference between mGlu2 and mGlu3 VFT appears at α-helix 7 and loop 7 (Fig.5A-B and 
supplemental Fig. 6). Whereas loop 7 adopts a straight conformation in mGlu2, it is longer and curled in 
mGlu3 because of α-helix 7 unfolding. This occurrence results in a critical difference at the dimer interface 
between the Acc protomers, which allows several additional interactions with the facing monomer. A closer 
look at the mGlu3 structures suggests that Cl- bound at site 2 could coordinate this network of interactions 
between the two lobes, tightening the closed VFT. In particular, Cl- may bridge S152 (lobe 1, loop 3) and R277 
(lobe 2, loop 8) in the agonist-induced closed VFT conformation (Fig. 5C-D right panel). Due to the ionic 
nature of the chloride, the interaction between S152 and R277 is stronger compared to that with a neutral water 
molecule (Rozas et al., 2008) (Fig. 5D central and right panel). Thereby, Cl- may act as a “Cl- lock” underlying 
the high agonist affinity by stabilizing the glutamate-induced closed conformation of mGlu3 VFT (Fig. 5 and 
6).  
To verify our hypothesis, we mutated mGlu3 S152 that seems to be crucial in Cl- binding into an aspartate 
(as in mGlu2) or an alanine and measured receptor activation by TR-FRET assay and signaling activity by Ca2+ 
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mobilization (Fig.5E, supplemental Fig.6B-D and supplemental table 2). Glutamate potencies of mGlu3 
S152A and mGlu3 S152D were not changed compared to the WT receptor in high Cl- buffer (supplemental 
Fig.6B). However, both S152A and S152D mutations abolished the receptor’s basal activity. Indeed, FRET 
ratios measured in high Cl- were similar to the WT receptor in low Cl- (Fig.7C). Ca2+ mobilization data 
indicated signaling activity was rescued for both mutants in high Cl- buffer, in comparison to the WT 
(supplemental Fig.6C). Regarding Cl- sensitivity, the mGlu3 S152D mutant exhibited a reduced Cl- 
sensitivity, similar to the mGlu2 receptor (supplemental table 2). Mutations did not change expression of the 
receptor (supplemental Fig.6D). Taken together, these data confirmed the involvement of Cl- binding site 2 
in mGlu3 receptor’s activity and unravel the key role of S152 on ion stabilization.  
At a molecular level, these data may be interpreted in terms of stability of the active conformation of the 
receptor. With the mutants S152D and S152A of the mGlu3 receptor, the most stable network is similar to that 
at low Cl- concentrations and the high basal activity is thus not observed, resembling to what happens at mGlu2 
receptors.  
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DISCUSSION  
 
In this study, we investigated the molecular mechanisms underlying the atypical high-basal activity 
observed in cells expressing the mGlu3 receptor. Our main finding shows that it is not corresponding to a 
constitutive activity of the mGlu3 receptor in the absence of bound agonist. Instead, it results mostly from a 
Cl--mediated amplified response to low ambient glutamate concentrations, such as those measured in cell 
media. This strong positive allosteric modulation of glutamate by Cl- ions allows the mGlu3 receptor to sense 
and efficiently react to sub-micromolar concentrations of glutamate, making it the most sensitive member of 
mGluR family. 
Ion dependence of mGluRs activity has been previously reported, notably to Ca2+ and Cl- (Kuang and 
Hampson, 2006). While mGlu1 and mGlu3 receptors were demonstrated to be sensitive to Ca2+, Cl- modulation 
was reported for all mGluRs, with a lesser extent for the mGlu2 receptor (DiRaddo et al., 2014; Jiang et al., 
2014; Tora et al., 2015; Vafabakhsh et al., 2015). Of note, the cooperativity between an amino acid ligand and 
ions to stabilize the active conformation of the receptor is also observed in another receptor from the GPCR 
class C, the Ca2+ sensing receptor. This receptor is activated concomitantly both by Ca2+ ions and an L-amino 
acid, such as L-Phe, that binds in a pocket corresponding to the glutamate binding pocket in mGluRs (Zhang 
et al., 2014). Here, we showed that the mGlu3 receptor is particularly strongly potentiated by Cl- ions as 
compared to other mGluRs. This strong positive cooperativity between Cl- ions and glutamate occurs through 
a unique strengthened interaction network between the two lobes of the extracellular domain of the mGlu3 
receptor. This network acts as a “Cl--lock” that dramatically reinforces glutamate binding and function.  
Previously, both Ca2+ and Cl- ions were proposed to display agonist activity on the mGlu3 receptor (DiRaddo 
et al., 2015; Vafabakhsh et al., 2015). However, in our experiments, Cl- per se does not display direct agonism, 
as revealed by the glutamate insensitive mGlu3 mutant T174A, which is not activated by Cl-. We propose that 
what has been interpreted previously as Cl- direct agonism in very sensitive assays may correspond in fact to 
the potentiation by Cl- ions of the activity induced by residual ambient glutamate. Indeed, cells are 
constitutively releasing glutamate in extracellular media. We have recorded concentrations ranging from 0.6 
to more than 5 µM. These glutamate concentrations are in line with those measured in another recent 
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publication (Doornbos et al., 2018). Thus, Cl- ions are pure positive allosteric modulators of the mGlu3 
receptor.  
It is unlikely to observe the occurrence of rapid Cl- concentration changes compatible with dynamic 
modulation of mGlu3 receptor activity. Short-term variations occur during transport or synaptic activities 
where rapid Cl- fluxes through GABA or glycine-gated ion channels modify Cl- concentrations (Staley et al., 
1995). We have previously evaluated the discrete variations of Cl- concentrations in the synaptic cleft during 
GABAergic events in physiological or pathological conditions (Tora et al., 2015). We found that multiple 
synaptic events can modify synaptic Cl- concentrations up to 25 mM. Long-term changes in Cl- concentrations 
can be observed during maturation (Ben-Ari et al., 2007), modifications of extracellular matrix (ECM) and 
pathologies (De Koninck, 2007; Kaila et al., 2014). Interestingly, fast extracellular Cl- changes due to synaptic 
activity and slow changes could be additive. Thus, in particular conditions, such as anoxia where variations of 
Cl- exceeding 30 mM can be observed (Jiang et al., 1992), Cl- variations could reach up to 55 mM. However, 
given the potency of Cl- on the mGlu3 receptor (~30 mM) as compared to the physiological extracellular Cl- 
concentration in mature CNS (~120 mM), the potentiation of mGlu3 receptor activity by Cl- ions is probably 
mostly constitutive. Other members of the mGluR family could be dynamically regulated by Cl-, such as the 
presynaptic mGlu4 receptor (Tora et al., 2015). Indeed, unlike the mGlu3 receptor, mGlu4 presents 
characteristics that makes it more susceptible to be actively regulated by discrete Cl- variations. First, this 
receptor is expressed in GABAergic synapses where rapid Cl- variations occur following opening of GABAA 
receptors. Second, the potency of Cl- on mGlu4 receptoris  close to the physiological Cl- concentration (~80 
mM) and presents a steep relationship between Cl- and glutamate-induced activity (with an NHill ~6). This 
means that small changes in Cl- concentration yield to large changes in response to glutamate. On the other 
hand, dramatic changes in Cl- homoeostatis occur during CNS maturation  (Ben-Ari et al., 2007). We can 
hypothesize that mGlu3 receptors should shift from a “dynamic” mode of glutamate response during the early 
stages to the highly-glutamate sensitive and sustained response mode described in the present study in mature 
stages. This should affect its biological functions in early stages, such as the crucial control of mGlu5-mediated 
neuroprotection described in Di Menna et al. (Di Menna et al., 2018). One can hypothesize that when 
extracellular Cl- concentrations are low in premature stages, mGlu3 receptor should be able to signal and 
regulate the release of neurotrophic factors from astrocytes, given its high Cl- sensitivity. However, in the 
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absence of specific data this remains purely speculative and further investigations will be needed to evaluate 
the impact of Cl- on mGluR function in the premature brain. In the mature brain, while it is unlikely to observe 
the occurrence of Cl- concentrations changes compatible with a significant modulation of mGlu3 receptor 
activity, a Cl- mediated rapid adaptation of the regulatory role of some mGluRs, such as mGlu4 receptors 
present on GABAergic terminals, could be observed.  
Although the overall structures of mGlu2 and mGlu3 VFTs are highly similar, two major differences can 
be observed: (i) the number of functional Cl- binding sites, one in mGlu2 versus two in mGlu3 receptors and 
(ii) the loop 7 in lobe 2 is longer in mGlu3 than in the mGlu2 receptor. These two particularities of the mGlu3 
receptor contribute to the building-up of a unique “Cl- lock” that greatly stabilizes the glutamate-induced closed 
conformation of its VFT. Indeed, as compared to mGlu2, the presence of Cl- in site 2 in mGlu3 receptor is 
coordinating a network of interactions between the two lobes, involving notably the twisted loop 7, that is 
tightening the closed VFT. As a result, the atypical high-basal activity of the mGlu3 receptor is not observed 
in the cognate mGlu2 receptor in which the Cl- lock is absent. The residue S152 seems to play a crucial role in 
Cl- binding and bridging between the lobes. This amino acid was previously reported to be involved in mGlu3 
Ca2+-based basal activity (Kubo et al., 1998; Vafabakhsh et al., 2015), but no Ca2+ ion was found in crystal 
structures at this location. Regarding literature, Ca2+ seems to play a role in mGlu3 receptor activity, but its 
binding(s) site(s) as well as its contribution to the receptor’s basal activity remains unclear. In contrast, in the 
mGlu2 receptor, the corresponding serine residue is mutated into an aspartate (D146), which disrupts Cl- 
binding at site 2, explaining divergence with mGlu3 receptors towards both Cl- sensitivity and basal activity. 
Prior to this study, D146 has been proposed to disrupt the cation-pi interaction and also the Cl- binding site 1, 
by engendering a flip of R271 (so called “arginine flip”), thus postulating there would be no Cl- binding sites 
in mGlu2 (DiRaddo et al., 2015). However, in recently released mGlu2 VFT crystal structure (Monn et al., 
2015b), the cation-pi interaction is intact and only one Cl- ion is found in site 1, which is consistent with our 
previous study and the present data (Tora et al., 2015). In addition, it is worth to mention that another Cl- ion 
is localized near the cation-pi in this structure, but at a different site from site 2, as it is found in only one 
protomer and therefore may be a crystallization artefact. Additional inter-lobe connections may also participate 
to the closed VFT stabilization, such as R249 (lobe 2, loop 7), which can bind to G51 (lobe 1, loop 1) in mGlu3 
receptors because of the unfolding of the α-helix 7 and a new conformation of loop 7 (Fig. 5C and D right 
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panels). The H-bond between R249 and G51 carbonyl is weaker than the salt bridge with D102 that occurs in 
mGlu2 (Fig.5C and D left panels), nevertheless this loss of stability is compensated by new interactions at the 
dimer interface between loop 7 and helix 6 of the other monomer (See Fig. 6 and supplemental Fig. 5). This 
interaction network could possibly explain why the two mGlu3 VFT monomers are closer than those of mGlu2. 
One can speculate that this proximity may further increase the stability of the active dimer resulting in the 
basal activity of the receptor at low glutamate concentrations. However, further studies will be necessary to 
determine more precisely the dimer interface and its involvement in receptor activation.   
The specific pathophysiological roles of the mGlu3 receptor are still poorly understood. Until recently, 
these studies have been hampered by the lack of selective tools discriminating between the cognate mGlu2 and 
mGlu3 receptors. Indeed, the orthosteric binding sites of these two receptors are 100% identical, making the 
identification of selective orthosteric ligands highly challenging. Thus, the first ligands available were selective 
for the group II mGluRs over other groups, but failed to discriminate between mGlu2 and mGlu3 receptors 
(Celanire et al., 2015). Still, mGlu2/3 ligands have been very helpful to highlight the involvement and the 
therapeutic potential of these receptors in different CNS disorders, notably in anxiety, schizophrenia, addiction, 
depression and chronic pain. Recently, several selective mGlu3 negative allosteric modulators (Engers et al., 
2015) or orthosteric ligands (Monn et al., 2018; Monn et al., 2015b) have been identified. The selectivity of 
these newly discovered orthosteric ligands lies behind their interaction with amino acids residing at the 
periphery of the glutamate binding site of the mGlu3 receptor (Monn et al., 2018). Indeed the crystal structure 
of LY2794193, a selective mGlu3 agonist, bound to mGlu3 VFT (PDB ID 6B7H) reveals that its 
methoxyphenyl substituent pushes away R277 but does not prevent the stabilization of the active dimer with 
the curled loop7 (Supplemental Fig. 7) (Monn et al 2018). On the other hand, a similar perturbation of R271 
in mGlu2 decreases significantly the receptor activation. Thus, it appears that targeting the Cl- binding sites of 
mGlu3 receptor provide an interesting way to overcome the difficulty of designing selective orthosteric drugs. 
Interestingly, this approach is also valid for other mGluRs. For example, the first mGlu4 receptor selective 
orthosteric agonist named LSP4-2022 is a dualsteric/bitopic ligand targeting both the glutamate- and the Cl- 
binding pockets of the mGlu4 receptor (Goudet et al., 2012; Selvam et al., 2018). Hopefully, new selective 
ligands will help to better define the particular roles of mGlu3 receptors. 
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Interestingly, mGlu2 and mGlu3 receptors differ notably by their cellular distribution. Whereas mGlu2 
receptors are mostly neuronal, mGlu3 receptors are expressed both in glia and in neurons. In neurons, mGlu3 
receptors are present at the post-synapse and in presynaptic elements (Tamaru et al., 2001) where their 
activation reduces synaptic activity and plasticity (Harrison et al., 2008). Interestingly, a functional partnership 
between neuronal mGlu3 receptors and mGlu5 receptors has recently been described, in which activation of 
mGlu3 receptors amplifies mGlu5 receptor signaling and shapes the ability of mGlu5 receptors to either amplify 
or restrain neuronal toxicity (Di Menna et al., 2018). In astrocytes, mGlu3 receptors have been shown to 
regulate important functions such as the release of astrocytic glutamate and other factors (Aronica et al., 2005; 
Corti et al., 2007; Nicoletti et al., 2015), the re-uptake of glutamate (Aronica et al., 2003), nitrate homeostasis 
(Wang et al., 2016) and are involved in neuroprotection (Battaglia et al., 2015; Corti et al., 2007). By promoting 
glutamate sensing in the extracellular space, through the molecular mechanisms described in this study, the 
mGlu3 receptor could react effectively to concentrations of glutamate below the micromolar range. This might 
confer mGlu3 receptor the ability to regulate the basal tone of glutamate release from neuronal presynaptic 
elements, as well as basal release of neuroprotective factors, thereby participating to the fine regulation of 
glutamate reuptake by glia.   
Given the numerous physiological and pathological actions of glutamate, it is crucial to control acutely 
extracellular glutamate concentrations in the brain. Indeed glutamate becomes neurotoxic at elevated 
extracellular concentrations and glutamate dysregulation is associated to many CNS disorders. Different actors 
ensure the control of glutamate homeostasis.  Transporters are maintaining low concentrations of synaptic and 
extrasynaptic glutamate. While ionotropic glutamate receptors are responsible of the fast-synaptic response to 
glutamate, mGluRs are responsible for its slow neuromodulatory actions. Group I mGluRs positively modulate 
responses to glutamate while group II and group III receptors are decreasing neuronal activity by 
downregulating the release of neurotransmitters. Interestingly, the eight members of the mGluR family display 
different affinities for glutamate. Three members present submicromolar affinity for glutamate: mGlu1 with 
0.3 µM (Mutel et al., 2000; Thomsen et al., 1993), mGlu5 with 0.5 µM (Mutel et al., 2000) and mGlu3 which 
Ki values range from 0.041 to 0.9 µM (Johnson et al., 1999; Laurie et al., 1995; Schweitzer et al., 2000) and 
0.9 µM in the present study. While the mGlu3 receptor affinity for glutamate is in the same range than the ones 
of mGlu1 or mGlu5 receptors, its relatively high glutamate affinity combined to its unique Cl- lock favoring the 
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agonist-induced state makes the mGlu3 receptor able to sense and fully respond to submicromolar glutamate 
concentrations. This could enable mGlu3 receptors to play a role in the regulation of basal conditions with low 
tone of glutamate. Other members of the family, mGlu2, 4, 6 and 8 receptors present intermediate affinities, in the 
micromolar range, for glutamate, (Cartmell et al., 1998; Eriksen and Thomsen, 1995; Schweitzer et al., 2000; 
Wright et al., 2000). On the opposite side of the spectrum, the mGlu7 receptor is activated by millimolar 
concentrations of glutamate, with an affinity around 900 µM (Wright et al., 2000). This receptor is located in 
the synaptic grid where glutamate is released and can reach occasionally such high concentrations. Contrary 
to mGlu3 receptor, the role of mGlu7 receptor would then be to react to the highest concentrations of glutamate 
and may ensure a role of safety valve. This mGluRs large spectrum of glutamate sensitivity associated to their 
widespread synaptic, non-synaptic and glial distribution allows them to participate to a fine neuroadaptation 
of the CNS.  
In conclusion, we demonstrated that the atypical high-basal activity of the mGlu3 receptor results mostly 
from its activation by low ambient glutamate concentrations. This is due to a unique interaction network 
located in the extracellular domain of the mGlu3 receptor. This network acts as “Cl- lock” that is strongly 
stabilizing the glutamate-induced active conformation of the receptors.  This strong allosteric control of the 
mGlu3 receptor by physiological Cl- ions allows it to sense and respond efficiently to low concentrations of 
glutamate. Thus, the various mGluR subtypes appear as a family of glutamate sensors able to respond to a 
wide range of conditions, from high nanomolar to millimolar concentrations of glutamate. Among them, mGlu3 
receptor is the most sensitive member of this family, able to mediate sustained responses to low tone of 
glutamate.  
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FIGURES 
 
Figure 1: The Venus flytrap domain is required for mGlu3 receptor high basal activity. 
(A) Signaling activity of the eight mGluRs quantified by inositol monophosphate (IP1) production under 
vehicle (VEH) or 1 mM glutamate (Glu) stimulation. HTRF ratio is inversely proportional to IP1 levels. 
Among all mGluRs, mGlu3 receptor low HTRF ratio in vehicle condition suggests a high basal activity. Each 
data point corresponds to means ± SEM of at 6 experiments. (B-C) Glutamate concentration-response curves 
of mGlu2 and mGlu3 receptors chimeras determined by IP1 (B) and TR-FRET mGlu sensor (C) assays. 
Contrary to mGlu2 receptor (full circles), mGlu3 receptor (full squares) concentration-response curve is nearly 
flat due to its high basal activity. This is abolished when mGlu3 VFT is replaced by the one from mGlu2 
receptor (VFT2/TMD3, open squares). In contrast, fusion of mGlu3 VFT to mGlu2 TMD (VFT3/TMD2 
chimera, open circles) results to an mGlu3 receptor-like concentration response curve, indicating mGlu3 VFT 
supports the receptor's high basal activity. Each data point corresponds to means ± SEM of at 3 experiments.  
(D) Principle of TR-FRET mGlu sensors. Concentration-response curve parameters are listed in supplemental 
table 1. *** p<0.001 according to One-way ANOVA with Dunnett’s post test. CRD: Cysteine-rich domain; 
ECD: Extracellular domain; Glu: Glutamate; TMD: Transmembrane domain; VEH: vehicle; VFT: Venus 
flytrap. 
 
Figure 2: Glutamate binding is required for mGlu3 receptor high basal activity. 
 (A) TR-FRET ratios measured in mGlu3 expressing cells in absence (VEH) and presence of 1mM 
glutamate (Glu) or the competitive antagonist LY341495. Basal activity of mGlu3 receptors is decreased by 
LY341495 addition. Each data point corresponds to means ± SEM of at 11 experiments. (B) Glutamate 
concentration-response curves of mGlu3 T174A (lozenges) and WT receptors (circles) determined by TR-
FRET mGlu sensor assay. The glutamate-insensitive mutant T174A did not show low FRET ratios in the 
vehicle condition (VEH) as compared to the WT, indicating basal activity of the receptor is linked to glutamate. 
Each data point corresponds to mean ± SEM of at 3 experiments. Data are normalized by VEH FRET window 
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(A) or top and bottom the WT concentration-response curve (B). ECD: Extracellular domain; Glu: Glutamate; 
TMD: Transmembrane domain; VEH: vehicle. 
Figure 3: Extracellular chloride ions enhance mGlu3 receptor activation by glutamate. 
(A) Glutamate concentration-response curves determined on mGlu3 receptors by measuring TR-FRET 
ratios in a buffer containing a standard Cl- concentration (high Cl-, full circles) and in a Cl- - depleted buffer 
(low Cl-, open circles). Data indicate that Cl- both potentiate basal activity of the receptor (VEH condition) and 
glutamate potency. The latter can be re-calculated by extrapolation in the high Cl- buffer, by subtracting the basal 
activity (red curve). Each data point corresponds to means ± SEM of 11 experiments. Extrapolated glutamate 
potency value is listed in supplemental table 2, and matches glutamate Ki determined in supplemental figure 2. (B) 
TR-FRET experiments in increasing Cl- concentrations indicate both mGlu3 basal activity and glutamate 
potency are potentiated by Cl- in a concentration-dependent manner. Each data point corresponds to means ± 
SEM of 5 experiments.  (C) Cl- concentration-response curves in absence (VEH, open squares) and presence 
of 30 μM glutamate (EC80, full squares). Each data point corresponds to means ± SEM of 5 experiments. Cl- 
potency was estimated to 30.98 mM with glutamate. In vehicle condition, Cl- potency was extrapolated to 
470.10 mM. (D) Glutamate concentration-response curve on mGlu2 receptors determined by TR-FRET mGlu 
sensor assay. Each data point corresponds to means ± SEM of 3 experiments.  (E) TR-FRET levels on mGlu3 
receptors in absence of ligand (VEH) and in presence of 1 mM LY341495 (LY34, competitive antagonist) or 
glutamate (Glu) in high and low Cl- buffers. mGlu3 basal response (VEH) in high Cl- is abolished by LY341495 
to a similar FRET level observed in low Cl-. Each data point corresponds to mean ± SEM of 11 experiments. 
Data are normalized by largest signal window defined by top and bottom of the curve in low Cl-. Concentration-
response curve parameters are listed in supplemental table 2. Glu: glutamate; LY34: LY341495; VEH: vehicle. 
Figure 4: Chloride ions strongly favor glutamate-induced active conformation of mGlu3 receptors. 
 (A) TR-FRET ratios of mGlu3 WT and T174A receptors measured in absence (VEH) and presence of 30 
μM (EC80) glutamate. Each data point corresponds to means ± SEM of 11 (mGlu3 WT) and 3 experiments 
(mGlu3 T174A).  (B) Principle of smFRET applied to mGluRs. (C) Apparent FRET efficiency (EPR) of mGlu3 
WT and T174A purified ECDs in absence (VEH) and presence of 1 mM glutamate, measured in smFRET. 
These results correlate data in (A) and suggest that basal activity of mGlu3 receptor is due to Cl-potentiation of 
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glutamate-induced active conformation and not to an agonist activity of Cl-. Each data point corresponds to 
means ± SEM of 3 (mGlu3 WT) and 4 experiments (mGlu3 T174A). EPR values are shown in supplemental 
figure 4. *** p<0.001 according One-way ANOVA with Sidak’s post test. ECD: extracellular domain; Glu, 
glutamate (for TR-FRET experiments, EC80 i.e. 30μM as determined in WT high Cl- concentration-response 
curve; for smFRET, 1 mM); GPI: Glycosylphosphatidyl inositol; LY34, LY341495; n.s.: non significant; PLC: 
Phospholipase C; TMD: transmembrane domain; VEH, vehicle. 
 
Figure 5: Different molecular and structural determinants of glutamate and chloride binding in mGlu2 
and mGlu3 receptors  
(A-B) mGlu2 and mGlu3 Acc VFT 3D-structures (PDB 4XAQ and 5CNK). Monomers (blue trace) are 
displayed in panel A, front view of dimers (blue and green traces) in panel B. Halides at site 1 and 2 as defined 
in Tora et al 2015, are displayed with van der Waals spheres. In mGlu2 receptor, α-helix 7 holds 4 turns 
(colored in red and orange for the first turn) and loop 7 (between β-strand 7 and α-helix 7) adopts a straight 
conformation (orange). In mGlu3 receptor, α-helix 7 is made of only 3 turns (colored in red) as turn 1 is 
unfolded allowing loop 7 (in orange) to curl. Cα distances are displayed between green chain (Glu222 for 
mGlu2 receptor, Glu228 for mGlu3 receptor) and blue chain (Ser 246 and Val 253 for mGlu2 receptor, Ile252 
and Val259 for mGlu3 receptor). The hairpin structure preceding α-helix 1 (I47 to N61) is named loop 1 and 
colored in purple. (C) mGlu2 receptor (left panel): R243 (loop 7 in lobe 2) is tightly bound to D95 (loop 2 
between β-strand 2 and α-helix 2) and D146 (loop 3 between β-strand 3 and α-helix 3) in lobe 1 by two salt 
bridges, mGlu3 receptor (right panel) R249 is not binding to D102 (loop 2), the homologous residues to mGlu2 
D95 but to the carbonyl of G51 of loop 1 which is possible because of the twisted loop 7 in the active dimer. 
This distortion allows several inter-dimer interactions: I252 with A176, R253 and K 246 with E228. (D). The 
closed mGlu2 VFT is further stabilized by an ionic interaction between D146 (loop 3) and R271 (loop 8 
between β-strand 8 and α-helix 8) and a cation-Π interaction between Y144 (loop 3) and R271 in mGlu2 
receptor (left panel). In mGlu3 receptor, a similar cation-Π interaction between Y150 and R277 is present in 
the Resting closed closed dimer conformation, Rcc (PDB structure 2E4U) and in the Acc conformation (central 
and right panel). However, the distance is too long between S152 and R277 for a direct interaction. It is 
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mediated by a water molecule (red atom, central panel) in the Rcc conformation or by a halide (iodide in 
5CNK, violet atom, right panel) ion in the superstable Acc conformation (Supplemental Figure 7). Atom color 
code: C chain color, N blue, O red, Cl green, I violet. (E) Mutations of S152 in mGlu3 into an alanine (S152A, 
squares) or aspartate (S152D, triangles) both reduce receptor basal activity without significantly reducing 
glutamate potency in TR-FRET sensor assay. Each data point corresponds to mean ± SEM of 6 to 11 
experiments (see details in supplemental figure 2). Concentration-response curve parameters are listed in 
supplemental table S2. Glu: glutamate; VEH: vehicle. 
 
Figure 6. A unique “chloride lock” stabilizes the glutamate-induced active state of the mGlu3 receptor.  
(A-B) 3D-structures displaying the key residues involved in the stabilization of the closed state of the VFT 
of mGlu2 and mGlu3 receptors (PDB 4XAQ and 5CNK). Interactions are displayed as dashed lines. (C-D). 
Schematic representation of the interaction network in the cleft between the two lobes of the VFT of mGlu2 
and mGlu3 receptors. Color code see Figure 5. 
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Table 1 
 [Glutamate] (μM) 
Plated cells post-transfection (t=0) 
1x wash with sensor buffer - EAAC1 1,33 ± 0,12 
1x wash with sensor buffer + EAAC1 1,39 ± 0,23 
  
Plated cells before experiments (t=2h)  
in glutamax™ - EAAC1 3,27 ± 0,004 
in glutamax™ + EAAC1 0,59 ± 0,03 
  
Plated cells before experiments (t=5h)  
in glutamax™ - EAAC1 > 5 
in glutamax™ + EAAC1 1,36 ± 0,01 
  
Extracellular medium  
Glutamax™ 0,07 ± 0,01 
IP-One buffer 0,43 ± 0,03 
Ca2+/Sensor buffer ≈ 0 
  
 
Table 1: Extracellular media residual glutamate concentrations. 
Glutamate concentrations found in different media used in our transient expression system. Data were 
determined on supernatant from freshly washed plated cells after 24h transfection (t=0), 2 or 5h after 
medium change by Glutamax™ (before experiments, see material and methods section for details) and 
on various buffers. Effect of glutamate transporter EAAC1 co-expression was also assessed. Values 
represent mean ± S.E.M of n=3 experiments. Sensor and Ca2+ buffers correspond to high Cl- buffer 
composition. 
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Supplemental figure 1: Expression levels of mGlu2 and mGlu3 chimeras.
Quantification by fluorescence at 620nm on Lumi4-Tb labeled receptors transiently expressed in
HEK293 cells.



Supplemental figure 5
Supplemental figure 5: 3D Structures of VFT mGlu2 and mGlu3 receptor dimers in their activeconformation (Acc).
(A‐B) side view. (C) front view same figure as Fig.5. Color code see Fig.5. Comparison of dimers in A
and B, reveals a larger dimer contact surface in mGlu3 Acc which may be considered as a superstable
dimer conformation.
Supplemental figure 6: Molecular determinants of mGlu3 chloride lock
A. Sequence alignment of the 8 mGluRs performed using Align123 on Discovery Studio suite and then
optimized. Sequences were retrieved from Uniprot database (identifiers reported on the figure, middle
column) and only the ECD parts were used (residue interval in right column). Numbers correspond to
mGlu3R residue numbering. Blue color intensity is correlated by residue identity (dark), high similarity
(medium) or low similarity (light). Key position in Cl‐ binding are indicated in red (site 1) and yellow
(site 2). mGlu2/3R cation‐pi interlobe connection amino‐acids are in orange. Loop intervals indicated
with black double arrows. B. Bar plot of mGlu3 mutants pEC50 values determined by TR‐FRET mGlu
sensor assay in high‐Cl (open) and low‐Cl (hatched) media. C. Calcium mobilisation assay of mGlu3
receptor mutants in high‐Cl medium. Data are normalized by TR‐FRET largest window defined by top
and bottom of the mGlu3 WT dose‐response curve in low‐Cl. D. Expression of HA SNAP and HA mGlu3
constructs as determined by ELISA. Open bar: cell surface expression; hatched bar: total expression. All
constructs dose‐response parameters are listed in supplemental table 2. Glu: glutamate. VEH: vehicle.
A
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Supplemental figure 7
Supplemental figure 7: LY2794193, selective mGlu3 agonist bound to mGlu3 binding site (Monn et al 2018)
The phenyl substituent of LY2794193 pushes R277 but keeping a cation‐ interaction instead of with Y150. The 
curled loop 7 (brown) that stabilizes the active dimer is maintained and activation of mGlu3 occurs. At mGlu2, the 
analogous R271 is pushed similarly but the disruption of its bindings seems to prevent the stabilization of the active 
conformation of the receptor. Consequently, mGlu2 activation is notably decreased. 
SUPPLEMENTAL TABLES 
Supplemental table 1 
 
IP1  
Receptor Agonist 
pEC50 
(EC50  μM) 
Base 
(%) 
N 
mGlu3 WT 
Glutamate 
 
- 38,76 ± 3,00 3 
mGlu2 WT 
4,79 ± 0,07 
(16,22) 
100,00 ± 0,00 3 
 
VFT2/TMD3 
4,56 ± 0,08 
(27,54) 
148,47 ± 12,48 3 
VFT3/TMD2 - 41,69 ± 4,57 3 
TR-FRET sensor    
Receptor Agonist 
pEC50 
(EC50  μM) 
Base 
(%) 
N 
mGlu3 WT 
Glutamate 
 
5,30 ± 0,14 
(5,01) 
15,22 ± 3,01 3 
mGlu2 WT 
4,99 ± 0,13 
(10,23) 
100,00 ± 0,00 3 
 
VFT2/TMD3 
4,71 ± 0,16 
(19,50) 
111,27 ± 1,19 3 
VFT3/TMD2 
6,06 ± 0,08 
(0,87) 
7,84 ± 2,22 3 
 
Supplemental table 1:  Concentration-response curves parameters of mGlu2-mGlu3 chimeras. 
Potency (pEC50) and basal response (vehicle stimulation) of TR-FRET sensors and IP1 curves are derived 
from data normalized by mGlu2 WT window (top and bottom of mGlu2 curve). Parameters values represent 
the mean ± SEM from three experiments (N) performed in triplicates. 
- : Not Determined 
  
Supplemental table 2 
 
Receptor Agonist High Cl- buffer Low Cl- buffer N Chloride sensitivity 
Calcium mobilization 
pEC50 
(EC50  μM) 
Emax 
(%WT) 
nH 
pEC50 
(EC50  μM) 
Emax 
(%WT) 
nH  
ΔpEC50 
(EC50 fold) 
mGlu3 
WT 
Glutamate 
 
- - - 
5,27 ± 0,12 
(5,37) 
97,99 ± 
2,66 
2,00 ± 
0,28 7 - 
mGlu3 
S152A 
6,10 ± 0,30 
(0,79) 
125,44 ± 
4,16 
1,97 ± 
0,51 
4,73 ± 0,06 
(18,62) 
119,83 ± 
7,94 
2,51 ± 
0,41 5 
-1,37 ± 0,31 
(23,44) 
mGlu3 
S152D 
6,56 ± 0,13 
(0,28) 
119,68 ± 
5,80 
1,18 ± 
0,16 
6,14 ± 0,04 
(0,72) 
107,18 ± 
2,14 
1,46 ± 
0,24 5 
-0,44 ± 0,11 
(2,75) 
TR-FRET sensor 
pEC50 
(EC50  μM) 
Base 
(%WT) 
nH 
pEC50 
(EC50  μM) 
Base 
(%WT) 
nH  
ΔpEC50 
(EC50 fold) 
mGlu3 
WT 
Glutamate 
5,62 ± 0,11 
(2,40) 
61,24 ± 
6,86 
1,24 ± 
0,09 
4,36 ± 0,09 
(43,65) 
99,98 ± 
0,02 
2,27 ± 
0,23 11 
-1,26 ± 0,07 
(18,20) 
 
6,05 ± 0,10 
(0,89) 
99.57 ± 
2,10 
0,71 ± 
0,13    Extrapol.  
mGlu3 
S152A 
5,22 ± 0,15 
(6,03) 
111,50 ± 
12,81 
1,94 ± 
0,14 
3,86 ± 0,07 
(138,04) 
147,13 ± 
8,22 
3,86 ± 
0,07 6 
-1,36 ± 0,15 
(22,91) 
mGlu3 
S152D 
5,30 ± 0,14 
(5,01) 
105,69 ± 
12,34 
1,88 ± 
0,26 
5,02 ± 0,11 
(9,55) 
109,77 ± 
11,22 
1,84 ± 
0,32 6 
-0,27 ± 0,05 
(1,86) 
mGlu3 
T174A 
- - - - - - 3 - 
mGlu2 
WT 
4,74 ± 0,19 
(18,20) 
95,61 ± 
2,33 
1,99 ± 
0,26 
4,14 ± 0,05 
(72,44) 
100,00 ± 
0,00 
1,41 ± 
0,27 3 
-0,60 ± 0,15 
(3,98) 
 
Supplemental table 2:  mGlu3 and mGlu2 constructs concentration-response curves parameters in high 
Cl- and low Cl- buffers. 
Potency (pEC50), maximum response (Emax), basal response (vehicle stimulation) and Hill slope from 
concentration-response curves obtained with calcium mobilization and TR-FRET sensor assays. Values in red 
represent the extrapolated parameters from the TR-FRET glutamate concentration-response curve in high Cl- 
without basal activity. Data are normalized by the maximum or basal response of the WT receptor in low Cl- 
buffer. Parameters values represent the mean ± SEM from at least three experiments (N) performed at least 
in duplicates. ΔpEC50 represent the loss of agonist potency due to chloride depletion. 
- : Not Determined. 
 
 
